129 related articles for article (PubMed ID: 26977827)
1. Drug Combo Adds No Benefit in Patients with Type 2 Diabetes.
Geurin MD
Am Fam Physician; 2016 Mar; 93(6):436-8. PubMed ID: 26977827
[No Abstract] [Full Text] [Related]
2. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
[TBL] [Abstract][Full Text] [Related]
3. Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.
Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; Nieuwdorp M; Groen AK; Cahen DL; van Raalte DH
Diabetes Obes Metab; 2016 Dec; 18(12):1217-1225. PubMed ID: 27451030
[TBL] [Abstract][Full Text] [Related]
4. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.
Barnett AH; Arnoldini S; Hunt B; Subramanian G; Hoxer CS
Diabetes Obes Metab; 2018 Aug; 20(8):1921-1927. PubMed ID: 29652101
[TBL] [Abstract][Full Text] [Related]
5. Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.
Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Pouwels PJ; Pieters-van den Bos IC; Hoekstra T; Diamant M; van Raalte DH; Cahen DL
Diabetologia; 2016 Dec; 59(12):2588-2593. PubMed ID: 27627981
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial.
Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Pieters-van den Bos IC; Vendrik KE; Hoekstra T; Bruno MJ; Diamant M; van Raalte DH; Cahen DL
Diabetes Care; 2017 Mar; 40(3):301-308. PubMed ID: 27998910
[TBL] [Abstract][Full Text] [Related]
7. [Modern antihyperglycaemic agents--what is the patient benefit?].
Siegmund T
MMW Fortschr Med; 2016 Apr; 158(7):45-8. PubMed ID: 27071585
[No Abstract] [Full Text] [Related]
8. New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
Simó R; Hernández C
Rev Esp Cardiol (Engl Ed); 2016 Nov; 69(11):1005-1007. PubMed ID: 27659856
[No Abstract] [Full Text] [Related]
9. Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.
McReelis KD; Lovshin JA
Can J Ophthalmol; 2017 Nov; 52 Suppl 1():S4-S7. PubMed ID: 29074013
[No Abstract] [Full Text] [Related]
10. [In patients with type 2 diabetes on metformin, the addition of which antihyperglycemic class among a sulfonylurea (glimepiride), a DPP-4 inhibitor (sitagliptin), a GLP-1 agonist (liraglutide), or basal insulin (glargine) is the most effective to achieve and maintain good glycemic control?].
Lanthier L; Mutchmore A; Plourde MÉ; Cauchon M
Rev Med Interne; 2023 Jan; 44(1):48-49. PubMed ID: 36443201
[No Abstract] [Full Text] [Related]
11. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure.
Arturi F; Succurro E; Miceli S; Cloro C; Ruffo M; Maio R; Perticone M; Sesti G; Perticone F
Endocrine; 2017 Sep; 57(3):464-473. PubMed ID: 27830456
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide: A Pilot Randomized Study.
Ferjan S; Janez A; Jensterle M
Metab Syndr Relat Disord; 2017 Dec; 15(10):515-520. PubMed ID: 29064743
[TBL] [Abstract][Full Text] [Related]
13. In type 2 diabetes, glargine and liraglutide each improved glycemic outcomes at 5 y vs. glimepiride or sitagliptin.
Brown K; Donato AA
Ann Intern Med; 2023 Jan; 176(1):JC8. PubMed ID: 36592465
[TBL] [Abstract][Full Text] [Related]
14. On combination therapy of diabetes with metformin and dipeptidyl peptidase IV inhibitors.
Hinke SA; McIntosh CH; Hoffmann T; Kühn-Wache K; Wagner L; Bär J; Manhart S; Wermann M; Pederson RA; Demuth HU
Diabetes Care; 2002 Aug; 25(8):1490-1; author reply 1491-2. PubMed ID: 12145269
[No Abstract] [Full Text] [Related]
15. Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus.
Thondam SK; Cross A; Cuthbertson DJ; Wilding JP; Daousi C
Diabet Med; 2012 Aug; 29(8):e205-10. PubMed ID: 22486277
[TBL] [Abstract][Full Text] [Related]
16. [Potential of pharmacological modulation of level and activity incretins on diabetes mellitus type 2].
Spasov AA; Chepljaeva NI
Biomed Khim; 2015; 61(4):488-96. PubMed ID: 26350740
[TBL] [Abstract][Full Text] [Related]
17. [Not Available].
Fischli S; Henzen C
Ther Umsch; 2017; 74(8):433-439. PubMed ID: 29461151
[No Abstract] [Full Text] [Related]
18. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist.
Baron HL
J Fam Pract; 2017 Oct; 66(10 Suppl):S17-S28. PubMed ID: 28991933
[TBL] [Abstract][Full Text] [Related]
19. Activation of Glucagon-Like Peptide-1 Receptor Ameliorates Cognitive Decline in Type 2 Diabetes Mellitus Through a Metabolism-Independent Pathway.
Li Q; Jia M; Yan Z; Li Q; Sun F; He C; Li Y; Zhou X; Zhang H; Liu X; Bu X; Gao P; He H; Zhao Z; Zhu Z
J Am Heart Assoc; 2021 Jul; 10(14):e020734. PubMed ID: 34250817
[TBL] [Abstract][Full Text] [Related]
20. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.
McCormick LM; Kydd AC; Read PA; Ring LS; Bond SJ; Hoole SP; Dutka DP
Circ Cardiovasc Imaging; 2014 Mar; 7(2):274-81. PubMed ID: 24503784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
